Bioethics News

Regulators Say Too Many Drugmakers Chasing Same Cancer Strategy

June 10, 2016

(Reuters) – A new type of cancer drug that takes the brakes off the body’s immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.S. regulator says too many companies are focused on the same approach. Dr. Richard Pazdur, head of the Food and Drug Administration’s office of oncology products, was referring to therapies designed to disable the PD-1 protein that tumors use to evade the immune system.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.